Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company focused on targeted radiotherapeutics for CNS cancers, has successfully addressed its Nasdaq listing compliance concerns. The company reported stockholders' equity of $3 million as of June 30, 2025, exceeding the minimum requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1).
This development follows a period of non-compliance identified on June 3, 2025, which led to a hearing before the Nasdaq Hearings Panel on July 15, 2025. The Panel granted Plus an extension to demonstrate compliance, and the company's recent Form 10-Q filing on August 14, 2025, confirms its return to compliance with the Equity Rule.
Plus Therapeutics (NASDAQ:PSTV), società farmaceutica in fase clinica specializzata in radioterapeutici mirati per i tumori del SNC, ha risolto con successo le problematiche relative alla conformità con la quotazione Nasdaq. La società ha riportato un patrimonio netto di 3 milioni di dollari al 30 giugno 2025, superando il requisito minimo di 2,5 milioni previsto dalla Nasdaq Listing Rule 5550(b)(1).
Questa evoluzione segue un periodo di non conformità segnalato il 3 giugno 2025, che ha portato a un'udienza davanti al Nasdaq Hearings Panel il 15 luglio 2025. Il Panel ha concesso a Plus un'estensione per dimostrare la conformità e il recente deposito del modulo 10-Q, datato 14 agosto 2025, conferma il ritorno della società alla conformità con la Equity Rule.
Plus Therapeutics (NASDAQ:PSTV), una compañía farmacéutica en fase clínica centrada en radiofármacos dirigidos para cánceres del SNC, ha resuelto con éxito sus problemas de cumplimiento de la cotización en Nasdaq. La empresa informó de un patrimonio neto de 3 millones de dólares al 30 de junio de 2025, superando el requisito mínimo de 2,5 millones establecido por la Norma de Cotización Nasdaq 5550(b)(1).
Este avance se produce tras un período de incumplimiento identificado el 3 de junio de 2025, que llevó a una audiencia ante el Nasdaq Hearings Panel el 15 de julio de 2025. El Panel concedió a Plus una prórroga para demostrar cumplimiento y la reciente presentación del Formulario 10-Q, con fecha 14 de agosto de 2025, confirma su retorno a la conformidad con la Equity Rule.
Plus Therapeutics (NASDAQ:PSTV)는 중추신경계(CNS) 암을 겨냥한 표적 방사성 치료제에 주력하는 임상 단계 제약사로, 나스닥 상장 규정 준수 문제를 성공적으로 해결했습니다. 회사는 2025년 6월 30일 기준으로 자본(주주지분) 300만 달러를 보고했으며, 이는 Nasdaq Listing Rule 5550(b)(1)에서 요구하는 최소 250만 달러를 상회합니다.
이번 조치는 2025년 6월 3일 확인된 비준수 상태에 따른 것으로, 2025년 7월 15일 나스닥 심리위원회(Nasdaq Hearings Panel) 심리가 진행되었습니다. 위원회는 Plus에 준수 입증을 위한 기한 연장을 허용했으며, 2025년 8월 14일 제출된 최근 Form 10-Q가 자사의 Equity Rule 준수 복귀를 확인합니다.
Plus Therapeutics (NASDAQ:PSTV), une société pharmaceutique en phase clinique spécialisée dans les radiothérapeutiques ciblées pour les cancers du SNC, a résolu avec succès ses problèmes de conformité liés à la cotation Nasdaq. La société a déclaré des capitaux propres de 3 millions de dollars au 30 juin 2025, dépassant l'exigence minimale de 2,5 millions prévue par la Nasdaq Listing Rule 5550(b)(1).
Cette évolution fait suite à une période de non-conformité identifiée le 3 juin 2025, qui a entraîné une audience devant le Nasdaq Hearings Panel le 15 juillet 2025. Le Panel a accordé à Plus une prolongation pour démontrer sa conformité, et le dépôt récent du formulaire 10-Q en date du 14 août 2025 confirme le retour de la société en conformité avec la Equity Rule.
Plus Therapeutics (NASDAQ:PSTV), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf zielgerichtete Radiotherapeutika für ZNS-Tumoren spezialisiert hat, hat seine Nasdaq-Listing-Compliance-Angelegenheiten erfolgreich geklärt. Das Unternehmen meldete zum 30. Juni 2025 ein Eigenkapital von 3 Mio. US-Dollar und liegt damit über der Mindestanforderung von 2,5 Mio. US-Dollar gemäß Nasdaq Listing Rule 5550(b)(1).
Dieser Fortschritt folgt auf eine am 3. Juni 2025 festgestellte Nichtkonformität, die zu einer Anhörung vor dem Nasdaq Hearings Panel am 15. Juli 2025 führte. Das Panel gewährte Plus eine Fristverlängerung zur Nachweisung der Compliance, und die kürzlich eingereichte Form 10-Q vom 14. August 2025 bestätigt die Rückkehr des Unternehmens zur Einhaltung der Equity Rule.
- Stockholders' equity increased to $3 million, exceeding Nasdaq's minimum requirement of $2.5 million
- Successfully maintained Nasdaq listing status by meeting compliance requirements
- Received extension from Nasdaq Hearings Panel to resolve compliance issues
- Previously fell below Nasdaq's minimum stockholders' equity requirement
- Company remains under Mandatory Panel Monitor through March 6, 2026
Insights
Plus Therapeutics regains Nasdaq compliance by exceeding minimum equity requirements, avoiding potential delisting.
Plus Therapeutics has successfully addressed a critical regulatory challenge by reporting
The resolution comes after a formal hearing process with the Nasdaq Hearings Panel on July 15, which granted Plus an extension to demonstrate compliance. This represents a significant regulatory milestone for the clinical-stage pharmaceutical company, which focuses on developing targeted radiotherapeutics for central nervous system cancers.
Maintaining Nasdaq listing status is crucial for public biotech companies like Plus Therapeutics. A delisting would have severely restricted access to capital markets, reduced share liquidity, diminished institutional investor interest, and potentially triggered defaults on financial agreements. For clinical-stage companies without consistent revenue streams, maintaining market access is particularly vital for ongoing financing of research and development activities.
While the company has resolved this immediate compliance concern, investors should note that Plus remains under a Mandatory Panel Monitor through March 2026, indicating ongoing regulatory scrutiny of its financial position. The company now awaits official confirmation from Nasdaq that it has satisfied the equity requirement condition.
HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders’ equity of
As previously reported, on June 3, 2025, the Nasdaq Listing Qualifications Department (the “Staff”) notified the Company that, as of March 31, 2025, the Company no longer satisfied the Equity Rule. Insofar as the Company was subject to a Mandatory Panel Monitor, as that term is defined under Nasdaq Listing Rule 5815(d)(4)(C), through March 6, 2026, with respect to the Equity Rule in particular, the Staff issued a delist determination following such non-compliance. On June 10, 2025, the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”), which stayed any further action by the Staff. The hearing was held on July 15, 2025.
As previously disclosed, on July 22, 2025, the Company was notified by Nasdaq that the Panel had granted the Company’s request for an extension to evidence compliance with the Equity Rule subject to the Company’s satisfaction of certain conditions.
As reflected in the Form 10-Q for the quarter ended June 30, 2025 filed August 14, 2025, the Company reported stockholders’ equity in excess of
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.
Investor Contact
CORE IR
investor@plustherapeutics.com
FAQ
What is Plus Therapeutics' (PSTV) current stockholders' equity as of June 30, 2025?
Why was Plus Therapeutics (PSTV) at risk of delisting from Nasdaq?
When did Plus Therapeutics (PSTV) receive the Nasdaq extension to comply with equity requirements?
What is Plus Therapeutics' (PSTV) main business focus?
